Related Experiment Videos
Postnatal thyroid hormone replacement in very preterm infants
J H Kok1, J M Briet, A G van Wassenaer
1Department of Neonatology, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands. J.H.Kok@amc.uva.nl
Seminars in Perinatology
|January 10, 2002
Summary
Transient hypothyroxinemia in preterm infants is common due to immature systems. While thyroid hormone (T4) is vital for development, T4 supplementation benefits are unclear, possibly aiding extremely preterm infants.
Area of Science:
- Neonatalogy
- Endocrinology
- Developmental Pediatrics
Background:
- Transient hypothyroxinemia is frequent in very preterm infants.
- It stems from immature hypothalamo-pituitary-thyroid axis, reduced maternal thyroxine (T4) transfer, impaired T4 metabolism, and neonatal illness.
- Thyroid hormone is crucial for brain, heart, and lung maturation, with low neonatal T4 linked to adverse outcomes.
Purpose of the Study:
- To evaluate the efficacy of thyroxine (T4) supplementation in improving clinical and neurodevelopmental outcomes for preterm infants.
- To address the limited randomized clinical trials investigating T4 supplementation in this population.
Main Methods:
- Review of existing randomized clinical trials on T4 supplementation in preterm infants.
- Analysis of the relationship between neonatal T4 levels and clinical/neurodevelopmental outcomes.
Main Results:
- Current evidence does not support routine T4 supplementation for all preterm infants.
- Preliminary indications suggest potential neurodevelopmental benefits of T4 in infants born before 27-29 weeks of gestation.
Conclusions:
- The use of supplemental T4 in preterm infants is not universally supported by current evidence.
- Further research through new trials is essential to determine the benefits of neonatal T4 administration in very preterm infants, particularly those born extremely prematurely.